AstraZeneca PLC Fourth Quarter and Full Year Results 2010

Thursday, 27 January 2011

David Brennan, Chief Executive Officer said:

"Our performance in 2010 underlines the strength and resilience of AstraZeneca’s business. Despite government pricing pressures and anticipated patent expiries in the US and Western Europe, our revenues remained in line with the previous year driven by excellent performance of our key brands and continued growth in Emerging Markets. This performance, combined with disciplined management of the business enabled us to deliver increased earnings, increase the dividend and return residual cash to shareholders through share repurchases."

Fourth quarter and full year results 2010

Announced on Thursday 27 January 2011



View the webcast 


  • Corporate and financial